Comparative Pharmacology
Head-to-head clinical analysis: HEXALEN versus MELPHALAN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXALEN versus MELPHALAN HYDROCHLORIDE.
HEXALEN vs MELPHALAN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
Melphalan is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
16 mg/m² intravenously over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks
None Documented
None Documented
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
1.5-2.5 h (terminal) in normal renal function; may be prolonged in renal impairment.
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Renal: 10-30% unchanged; fecal: 20-30% as metabolites; biliary: minor.
Category C
Category D/X
Alkylating Agent
Alkylating Agent